Amgen removes an Imdelltra treatment burden just as its DLL3 therapy approaches a much larger first-line opportunity
The FDA has reduced monitoring requirements around the first two Imdelltra doses, lowering an important logistical burden days after Amgen reported positive Phase 3 survival data in first-line extensive-stage small cell lung cancer.
